EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

D E Rathkopf, M R Patel, A D Choudhury, D Rasco, N Lakhani, J E Hawley, S Srinivas, A Aparicio, V Narayan, K D Runcie, H Emamekhoo, Z R Reichert und 10 weitere

Annals of Oncology · 2025-01 · 36 (1) · 76-88

DOI: 10.1016/j.annonc.2024.09.005 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Oncology, 2025-01. Verfasst von D E Rathkopf und 21 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York. Electronic address: rathkopd@mskcc.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Receptors, Androgen. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsReceptors, AndrogenHumansMaleAgedMiddle AgedAged, 80 and overMaximum Tolerated DoseProgression-Free SurvivalLigandsProstate-Specific Antigen

Stichwörter der Autor:innen

androgen receptor antagonistandrogen receptor pathway inhibitorligand binding domainligand-directed degradermCRPCprotein degradation

Substanzen

Androgen Receptor AntagonistsReceptors, AndrogenAR protein, humanLigandsProstate-Specific Antigen

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York. Electronic address: rathkopd@mskcc.org.
  • Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota.
  • Dana-Farber Cancer Institute, Boston.
  • START Center for Cancer Care, San Antonio.
  • START Midwest, Grand Rapids.
  • University of Washington, Fred Hutch Cancer Center, Seattle.

Förderung

  • NCI NIH HHS
  • U.S. Department of Defense
  • Bristol-Myers Squibb Company
  • Prostate Cancer Foundation
  • Daiichi Sankyo Europe
  • GlaxoSmithKline

Zitieren

APA

Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., …, & Armstrong, A. J. (2025). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology, 36(1), 76-88. https://doi.org/10.1016/j.annonc.2024.09.005

Vancouver

Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 2025;36(1):76-88. doi:10.1016/j.annonc.2024.09.005

BibTeX
@article{Rathkopf2025,
  author = {Rathkopf, D E and Patel, M R and Choudhury, A D and Rasco, D and Lakhani, N and Hawley, J E and Srinivas, S and Aparicio, A and Narayan, V and Runcie, K D and Emamekhoo, H and Reichert, Z R and Nguyen, M H and Wells, A L and Kandimalla, R and Liu, C and Suryawanshi, S and Han, J and Wu, J and Arora, V K and Pourdehnad, M and Armstrong, A J},
  title = {Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer},
  journal = {Annals of Oncology},
  year = {2025},
  volume = {36},
  number = {1},
  pages = {76--88},
  doi = {10.1016/j.annonc.2024.09.005}
}
Kostenlos starten →